Vera Therapeutics

VERA44

High Growth

$46.26arrow_drop_down5.46%-$2.67

High Growth

VERA44

$46.26

arrow_drop_down5.46%-$2.67

High Growth

Performance History

Key Stats
Open	$49.29
Prev. Close	$49.00
EPS	-2.59
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	45.64	49.08
52 Week Range	9.24	51.58

Ratios







EPS	-2.59

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Vera Therapeutics (VERA)

Vera Therapeutics, Inc. (VERA) is a biopharmaceutical company focused on developing novel therapies for the treatment of serious immunological and renal diseases. The company's lead product candidate, VERA-101, is a potent small molecule inhibitor of a protein called pSTAT3, which plays a key role in the immune system and is highly expressed in certain disease states. VERA-101 has shown promising results in preclinical studies and is currently being evaluated in a phase 1 clinical trial. The company believes that targeting pSTAT3 has the potential to address unmet medical needs in a range of therapeutic areas.

In recent news, Vera Therapeutics announced positive interim data from its ongoing phase 1 study of VERA-101. The data showed that VERA-101 was well-tolerated and demonstrated dose-dependent inhibition of pSTAT3 in patients with advanced solid tumors. These results validate the company's approach and support further development of VERA-101 as a potential treatment for a variety of cancers. The company plans to advance VERA-101 into phase 2 trials in the near future.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Marshall Fordyce M.D.
Headquarters: Brisbane
Employees: 49
Exchange: NASDAQ

Keep an eye on Vera Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Vera Therapeutics's (VERA) price per share?

The current price per share for Vera Therapeutics (VERA) is $46.26. The stock has seen a price change of -$2.68 recently, indicating a -5.47% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Vera Therapeutics (VERA)?

For Vera Therapeutics (VERA), the 52-week high is $51.58, which is 11.5% from the current price. The 52-week low is $9.24, the current price is 400.65% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Vera Therapeutics (VERA) a growth stock?

Vera Therapeutics (VERA) has shown an average price growth of -6.65% over the past three years. It has received a score of 89 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Vera Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Vera Therapeutics (VERA) stock price performance year to date (YTD)?

As of the latest data, Vera Therapeutics (VERA) has a year-to-date price change of 196.35%. Over the past month, the stock has experienced a price change of 15.68%. Over the last three months, the change has been 22.93%. Over the past six months, the figure is 10.3%.

help

Is Vera Therapeutics (VERA) a profitable company?

Vera Therapeutics (VERA) has a net income of -$95.99M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.86M, although specific revenue growth data is currently not available. The gross profit is $1.86M. Operating income is noted at -$102.01M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Vera Therapeutics (VERA)?

Vera Therapeutics (VERA) has a market capitalization of $2.93B. The average daily trading volume is 46.55, indicating the stock's liquidity and investor engagement.

News

VERA THERAPEUTICS

PUBLIC OFFERING

IMMUNOLOGICAL DISEASES

IGAN

LUPUS NEPHRITIS

Oct 28, 2024

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

VERA THERAPEUTICS

ATACICEPT

IMMUNOGLOBULIN A NEPHROPATHY

IGAN

KIDNEY FUNCTION

Oct 26, 2024

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

VERA THERAPEUTICS

INDUCEMENT AWARDS

STOCK OPTIONS

RESTRICTED STOCK UNITS

NEW EMPLOYEES

Jul 5, 2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

DIRECTORS AND OFFICERS

Jun 11, 2024

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

CHANGES IN COMPANY'S OWN SHARES

Jun 7, 2024